AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
+4.14%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$100M
AUM Growth
+$100M
(-25%)
Cap. Flow
-$37.3M
Cap. Flow
% of AUM
-37.26%
Top 10 Holdings %
Top 10 Hldgs %
26.12%
Holding
294
New
64
Increased
34
Reduced
105
Closed
85
Top Buys
| 1 |
Eli Lilly
LLY
|
$4.74M |
| 2 |
UnitedHealth
UNH
|
$3.6M |
| 3 |
Johnson & Johnson
JNJ
|
$2.63M |
| 4 |
AbbVie
ABBV
|
$2.31M |
| 5 |
Thermo Fisher Scientific
TMO
|
$2.17M |
Top Sells
| 1 |
Rithm Capital
RITM
|
$4.32M |
| 2 |
Harmony Biosciences
HRMY
|
$3.88M |
| 3 |
Galapagos
GLPG
|
$3.12M |
| 4 |
EFC
Ellington Financial
EFC
|
$2.6M |
| 5 |
Neurocrine Biosciences
NBIX
|
$2.57M |
Sector Composition
| 1 | Healthcare | 54.58% |
| 2 | Real Estate | 7.4% |
| 3 | Industrials | 5.96% |
| 4 | Financials | 5.87% |
| 5 | Technology | 4.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Datadog
DDOG
$46.1B
| $32.4K | 0.03% |
227
-40
| -15% | -$5.72K |
|
202
Mercado Libre
MELI
$119B
| $30.6K | 0.03% |
18
-3
| -14% | -$5.1K |
|
203
Woodward
WWD
$14.8B
| $29.8K | 0.03% |
179
-31
| -15% | -$5.16K |
|
204
CrowdStrike
CRWD
$102B
| $28.7K | 0.03% |
84
-15
| -15% | -$5.13K |
|
205
Elastic
ESTC
$8.98B
| $28.5K | 0.03% |
288
-51
| -15% | -$5.05K |
|
206
Zscaler
ZS
$40.8B
| $22.7K | 0.02% |
126
-22
| -15% | -$3.97K |
|
207
Snowflake
SNOW
$76.4B
| $21.6K | 0.02% |
140
-24
| -15% | -$3.71K |
|
208
iShares MSCI Austria ETF
EWO
$106M
| $16.9K | 0.02% |
805
-3,946
| -83% | -$82.7K |
|
209
Super Micro Computer
SMCI
$24.1B
| $12.8K | 0.01% |
421
+372
| +759% | +$11.3K |
|
210
Acadia Pharmaceuticals
ACAD
$4.38B
| – | – |
-40,000
| Closed | -$615K |
|
211
Enact Holdings
ACT
$5.49B
| – | – |
-42,367
| Closed | -$1.54M |
|
212
AGNC Investment
AGNC
$10.2B
| – | – |
-84,646
| Closed | -$885K |
|
213
Amphastar Pharmaceuticals
AMPH
$1.42B
| – | – |
-30,000
| Closed | -$1.46M |
|
214
Apellis Pharmaceuticals
APLS
$3.58B
| – | – |
-47,500
| Closed | -$1.37M |
|
215
argenx
ARGX
$43.6B
| – | – |
-4,500
| Closed | -$2.44M |
|
216
Alphatec Holdings
ATEC
$2.33B
| – | – |
-370,000
| Closed | -$2.06M |
|
217
Axsome Therapeutics
AXSM
$6.18B
| – | – |
-10,500
| Closed | -$944K |
|
|
BCYC
218
Bicycle Therapeutics
BCYC
$513M
| – | – |
-37,500
| Closed | -$849K |
|
219
BioMarin Pharmaceuticals
BMRN
$11.4B
| – | – |
-32,500
| Closed | -$2.28M |
|
220
Perspective Therapeutics
CATX
$255M
| – | – |
-80,000
| Closed | -$1.07M |
|
221
Cognex
CGNX
$7.41B
| – | – |
-15,000
| Closed | -$608K |
|
222
CG Oncology
CGON
$2.13B
| – | – |
-1,000
| Closed | -$37.7K |
|
223
Coherus Oncology, Inc. Common Stock
CHRS
$144M
| – | – |
-330,000
| Closed | -$343K |
|
224
Celldex Therapeutics
CLDX
$1.52B
| – | – |
-30,000
| Closed | -$1.02M |
|
225
Cytokinetics
CYTK
$5.91B
| – | – |
-12,500
| Closed | -$660K |
|